DocGo (NASDAQ:DCGO – Get Free Report) had its price target cut by investment analysts at BTIG Research from $15.00 to $13.00 in a research note issued to investors on Tuesday, FlyOnTheWall reports. BTIG Research’s target price points to a potential upside of 145.75% from the company’s previous close.
DCGO has been the subject of a number of other research reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $13.00 price objective on shares of DocGo in a research report on Thursday, September 14th. Needham & Company LLC reiterated a “buy” rating and issued a $14.00 price target on shares of DocGo in a research report on Monday. Stifel Nicolaus restated a “buy” rating and set a $12.00 price objective on shares of DocGo in a report on Monday. Finally, Northland Securities raised their target price on shares of DocGo from $15.00 to $16.00 in a report on Tuesday, August 8th.
DocGo Stock Down 7.2 %
DocGo (NASDAQ:DCGO – Get Free Report) last issued its quarterly earnings results on Monday, August 7th. The company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.05). The business had revenue of $125.49 million during the quarter, compared to analyst estimates of $119.64 million. DocGo had a net margin of 1.27% and a return on equity of 3.20%. On average, equities analysts predict that DocGo will post 0.09 EPS for the current fiscal year.
Insiders Place Their Bets
In other news, General Counsel Ely D. Tendler sold 10,000 shares of the company’s stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $8.75, for a total value of $87,500.00. Following the transaction, the general counsel now owns 23,088 shares in the company, valued at approximately $202,020. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other DocGo news, General Counsel Ely D. Tendler sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $8.75, for a total value of $87,500.00. Following the transaction, the general counsel now owns 23,088 shares in the company, valued at approximately $202,020. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Adriaan Stephanus Oberholzer sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $10.15, for a total transaction of $507,500.00. Following the completion of the transaction, the insider now owns 1,193,413 shares in the company, valued at approximately $12,113,141.95. The disclosure for this sale can be found here. In the last ninety days, insiders sold 62,000 shares of company stock worth $613,000. 13.78% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of DCGO. Marathon Capital Management lifted its holdings in shares of DocGo by 10.9% during the 4th quarter. Marathon Capital Management now owns 251,140 shares of the company’s stock valued at $1,776,000 after buying an additional 24,690 shares during the last quarter. Royce & Associates LP bought a new stake in DocGo in the first quarter worth approximately $2,154,000. Cannell Capital LLC bought a new stake in DocGo in the fourth quarter worth approximately $2,584,000. Moody National Bank Trust Division bought a new stake in DocGo in the second quarter worth approximately $300,000. Finally, P.A.W. Capital Corp increased its stake in shares of DocGo by 100.0% during the 1st quarter. P.A.W. Capital Corp now owns 320,000 shares of the company’s stock worth $2,768,000 after purchasing an additional 160,000 shares during the last quarter. Hedge funds and other institutional investors own 52.14% of the company’s stock.
DocGo Company Profile
DocGo Inc provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services.
- Five stocks we like better than DocGo
- How to Invest in Lithium and Lithium Stocks
- 2 Beauty Stocks Beaten By the Ugly Stick But Ready to Rally
- Find and Profitably Trade Stocks at 52-Week Lows
- Got Nuclear? Three Stocks To Play Energy’s Next Frontier
- 3 Monster Growth Stocks to Buy Now
- The Top 4 Utilities for Value, Yield, and Upside Potential
Receive News & Ratings for DocGo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DocGo and related companies with MarketBeat.com's FREE daily email newsletter.